Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

Abstract

Treatment with CPHPC followed by an anti-SAP antibody safely triggered clearance of amyloid deposits from the liver and some other tissues. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01777243.).